ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 22 Issue : 1
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey [Anatol J Cardiol]
Anatol J Cardiol. 2019; 21(6): 322-330 | DOI: 10.14744/AnatolJCardiol.2019.53498  

Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey

Yalın Tolga Yaylalı1, Ibrahim Başarıcı2, Burçak Kılıçkıran Avcı3, Murat Meriç4, Ümit Yaşar Sinan5, Hande Şenol6, Mehmet Serdar Küçükoğlu5, Zeki Öngen3
1Department of Cardiology, Faculty of Medicine, Pamukkale University; Denizli-Turkey
2Department of Biostatistics, Faculty of Medicine, Pamukkale University; Denizli-Turkey
3Department of Cardiology, Faculty of Medicine, Akdeniz University; Antalya-Turkey
4Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University; İstanbul-Turkey
5Department of Cardiology, Faculty of Medicine, Ondokuz Mayıs University; Samsun-Turkey
6Department of Cardiology, Institute of Cardiology, İstanbul University; İstanbul-Turkey

Objective: Risk stratification continues to evolve in pulmonary arterial hypertension (PAH). Our aim was to further confirm the risk assessment strategy in our cohort and to determine the most reliable model.
Methods: We enrolled incident patients with idiopathic PAH (IPAH), heritable, drug-induced, congenital heart disease (CHD), connective tissue diseases (CTD) subsets, and chronic thromboembolic pulmonary hypertension (CTEPH) from January 2008 to February 2018. Data from the baseline and subsequent follow-ups within 1 year of diagnosis were included. An abbreviated risk assessment strategy was applied using the following variables: functional class (FC), 6-minute walk distance (6 MWD), N-terminal pro–brain natriuretic peptide (NT-proBNP) or BNP, right atrial (RA) area, pericardial effusion, the mean RA pressure, cardiac index, and mixed venous oxygen saturation. Three different methods were applied to categorize patients.
Results: A total of 189 subjects (46±17 years, 23% male) were included. Sixty-one patients had died. The survival differed significantly between the risk groups both at diagnosis and during the follow-up. Patients with a low-risk profile had a better survival rate. An abbreviated risk assessment tool predicted mortality at early follow-up in the entire group and CHD, CTD subsets, and CTEPH, separately. An overall mortality among risk categories was significantly different according to each categorization method. The most reliable model comprised FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up.
Conclusion: The abbreviated risk assessment tool may be valid for the PAH subsets and CTEPH. Echocardiographic variables do matter. A model comprising FC, 6 MWD, NT pro-BNP/BNP, and the RA area at the follow-up could be useful for better prognostication.

Keywords: chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, pulmonary arterial hypertension subsets, risk assessment, survival


Yalın Tolga Yaylalı, Ibrahim Başarıcı, Burçak Kılıçkıran Avcı, Murat Meriç, Ümit Yaşar Sinan, Hande Şenol, Mehmet Serdar Küçükoğlu, Zeki Öngen. Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey. Anatol J Cardiol. 2019; 21(6): 322-330

Corresponding Author: Yalın Tolga Yaylalı, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology